Molecular Partners (NASDAQ:MOLN) Friday reported proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators.
MOLN shares rose +8.91% premarket to $6.48.
The data validates the Switch-DARPin concept in vivo and MP0621’s potential as a next-generation therapeutic supporting hematopoietic stem cell transplantation, initially for the treatment of acute myeloid leukemia (AML) patients, Molecular Partners (MOLN) said in a statement.
The data will be presented on Friday in a poster session at the European Hematology Association (EHA) 2024 Hybrid Congress taking place June 13-16 in Madrid, Spain.
“MP0621 is our first candidate in this series, with the aim to clear HSCs effectively and safely, by targeting cKit, engaging innate immune cells via CD16a, and blocking CD47 only on cKit+ cells,” Anne Goubier, Ph.D., SVP Research & Early Development said.
HSCT offers a potential cure for patients with AML and other malignant and non-malignant diseases. However, the toxicity of pre-HSCT conditioning often requires that it is carried out with reduced intensity, increasing the likelihood that diseased cells remain in the bone marrow and lead to relapse, Molecular Partners (MOLN) said.
MP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025.